PubMed:33166694 / 1927-2133 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T16","span":{"begin":134,"end":142},"obj":"Disease"}],"attributes":[{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Till definitive therapy is available, continuing PEP with HCQ may be considered in suitable at-risk individuals for the prevention of COVID-19, as endorsed by many national/international health authorities."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T18","span":{"begin":49,"end":52},"obj":"Chemical"}],"attributes":[{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_18021"},{"id":"A19","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_44897"}],"text":"Till definitive therapy is available, continuing PEP with HCQ may be considered in suitable at-risk individuals for the prevention of COVID-19, as endorsed by many national/international health authorities."}

{"project":"LitCovid-PubTator","denotations":[{"id":"66","span":{"begin":49,"end":52},"obj":"Gene"},{"id":"67","span":{"begin":134,"end":142},"obj":"Disease"}],"attributes":[{"id":"A66","pred":"tao:has_database_id","subj":"66","obj":"Gene:5550"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Till definitive therapy is available, continuing PEP with HCQ may be considered in suitable at-risk individuals for the prevention of COVID-19, as endorsed by many national/international health authorities."}

{"project":"LitCovid-sentences","denotations":[{"id":"T19","span":{"begin":0,"end":206},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Till definitive therapy is available, continuing PEP with HCQ may be considered in suitable at-risk individuals for the prevention of COVID-19, as endorsed by many national/international health authorities."}